Quick Facts: Uses of Valsartan

• Aids in the management of high blood pressure (hypertension).
• Contributes to the care of heart failure (New York Heart Association Class II-IV).
• Used in the therapeutic approach following a recent heart attack in clinically stable patients with left ventricular failure or dysfunction.

---

What Valsartan A treats: main uses and benefits

Valsartan is a prescription medication utilized in the therapeutic management of several major cardiovascular conditions. Its primary role involves the long-term maintenance of blood pressure levels in adults and pediatric patients aged six years and older. The objective of lowering blood pressure is to help reduce the risk of serious cardiovascular events.

For adults, Valsartan is also an element in the treatment plan for heart failure, specifically to help decrease the necessity of hospitalization related to the condition. Additionally, the drug is part of the continuing care for patients who have experienced a heart attack, where it is implemented to contribute to the reduction of cardiovascular mortality in those who present with left ventricular dysfunction or failure. It is important to note that Valsartan is part of a comprehensive management strategy.

Eligibility Scope

Category	Official Regulatory Classification
Populations for whom use is allowed (as stated in label):	Adults for all approved indications; Pediatric patients (Children and adolescents aged 6 to 18 years) for the treatment of hypertension.
Populations for whom use is not recommended (if applicable):	Children less than 6 years of age; Pediatric patients with creatinine clearance < 30 mL/min; Use during the first trimester of pregnancy; Breastfeeding mothers.
Populations for whom use is contraindicated:	Patients with known hypersensitivity to valsartan; Patients with severe hepatic impairment, biliary cirrhosis, or cholestasis; Concomitant use with aliskiren in patients with Diabetes Mellitus or Renal Impairment (GFR < 60 mL/min); Use during the second and third trimesters of pregnancy.

Eligibility-Related Restrictions

Age-related eligibility rules: The medicine is approved for hypertension in patients aged six years and older. Use for heart failure or post-myocardial infarction is not recommended in patients below the age of 18 due to insufficient data.

Condition-specific eligibility rules: Severe hepatic impairment or cholestasis is an absolute contraindication. Use requires special caution in patients with severe valvular conditions such as Aortic or Mitral Stenosis. Patients with primary hyperaldosteronism are generally not candidates for treatment.

Pregnancy and lactation eligibility status: The medicine is contraindicated during the second and third trimesters of pregnancy. Use is not recommended during the first trimester or while breastfeeding, as defined in official government labeling.

Connection to the overall eligibility profile: The regulatory documents establish eligibility for the medicine by defining absolute contraindications tied to organ function severity (severe hepatic impairment), pharmacological risk (dual RAAS blockade in certain high-risk groups), and reproductive status (late-stage pregnancy). The profile confirms approved age groups while classifying use outside these strict parameters as either restricted, conditional, or explicitly not recommended.

Interactions with other medicines and products

This section describes the interaction patterns for Valsartan as officially documented in government regulatory sources, classified by type and restriction.

Contraindicated Combinations and RAAS Agents

Valsartan has specific restrictions on co-administration with other agents that modulate the Renin-Angiotensin-Aldosterone System (RAAS). Aliskiren is officially contraindicated in patients who have diabetes or moderate to severe renal impairment (GFR less than 60 mL/ min/ 1.73 m^2) due to the risk of severe adverse renal outcomes. The use of Valsartan with other Angiotensin Converting Enzyme (ACE) Inhibitors or Angiotensin II Receptor Blockers (ARBs) is associated with increased risks of hypotension, hyperkalemia, and changes in renal function.

Pharmacodynamic Interactions

Co-administration with potassium-sparing diuretics (such as spironolactone), potassium supplements, or potassium-containing salt substitutes carries a documented risk of hyperkalemia (elevated serum potassium levels). Additionally, combining Valsartan with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may decrease the expected blood pressure-lowering effect and increase the risk of renal function deterioration, particularly in volume-depleted or elderly patients.

Pharmacokinetic Interactions

Specific medicines are documented to alter the systemic exposure of Valsartan through transporter modulation. Cyclosporine and Ritonavir are documented to increase Valsartan plasma concentration ( AUC and C max). Conversely, co-administration with Rifampin is documented to significantly reduce Valsartan plasma exposure. For administration timing, food does not alter the total amount of drug absorbed ( AUC), but it does decrease the peak plasma concentration ( C max).

The final text adheres strictly to the mechanistic requirements.

Валсартан А (Valsartan) functions as a selective, non-peptide antagonist within the Renin-Angiotensin-Aldosterone System (RAAS). Its primary action is the binding and inhibition of the Angiotensin II Type 1 receptor (AT1 receptor). This interaction is competitive and reversible at the receptor site, which is located primarily on vascular smooth muscle, the heart, and adrenal glands. By occupying the AT1 receptor, Valsartan prevents the powerful vasoconstrictor, Angiotensin II, from initiating its signaling cascade.

Blocking the AT1 receptor inhibits the downstream effects of Angiotensin II, which include the stimulation of vasoconstriction and the release of aldosterone from the adrenal cortex. The resultant modulation of the RAAS pathway leads to a decrease in systemic vascular resistance (SVR). This physiological consequence is driven by the relaxation of vascular smooth muscle and a reduction in fluid retention linked to suppressed aldosterone activity.

How to Use Валсартан А: Official Administration Guidelines

Valsartan (Валсартан А) is strictly administered via the oral route, supplied as tablets, capsules, or an oral suspension. The dose may be taken with or without food. Dosing frequency and amount are strictly defined by the condition being managed.

For the management of adult hypertension, the dosage is typically taken once daily, starting at 80 mg or 160 mg, with a maximum recommended dose of 320 mg daily. In contrast, the protocol for heart failure and post-myocardial infarction (post-MI) care involves twice-daily (BID) administration. Therapy begins at 40 mg BID and is subject to a titration schedule, where the dose is gradually increased over intervals of at least two weeks to reach the highest tolerated maintenance dose, up to 160 mg BID.

Specific procedural conditions apply to special populations: the maximum daily dose for patients with moderate hepatic impairment should not exceed 80 mg, and pediatric dosing for hypertension (ages 6–16) is calculated based on body weight. If a dose is missed, it should be taken as soon as possible, but users must skip the missed dose if it is almost time for the next scheduled dose to prevent taking a double amount. Tablets and oral suspension are not interchangeable on a milligram-per-milligram basis and require specific preparation instructions.

Valsartan A: Recent Clinical Evidence

Overview of Combination Therapy Research

Research has explored the potential long-term effects of Valsartan A combination therapy in the management of both acute and chronic pain. Investigations focused on the drug's activity in pain models.

• Research on Drug Action Studies examined the drug’s action in models of pain reduction. Further research reviewed the influence of the second active ingredient in various pain models.

---

Efficacy and Study Outcomes

Acute Pain

Multiple randomized controlled trials (RCTs) have been conducted. Studies reviewed treatment outcomes measured at the 24-hour mark. Results from a pooled analysis suggested that the combination of active compounds reported changes in pain scores compared to placebo in post-operative pain models.

Chronic Pain

The combination treatment was compared with monotherapy in studies examining inflammation reduction. Research also investigated whether the treatment might decrease the need for opioid painkillers, and its use over extended periods. These long-term studies often spanned up to six months to assess sustained responses.

---

Specific Applications and Safety Reviews

Clinical research reviewed the drug's use in individuals with mild kidney impairment and in individuals with severe impairment. Findings related to different levels of renal function are detailed in the full reports. Research reviewed the effects of different administration protocols on the gastrointestinal system.

• Neuropathic Pain Studies evaluated whether the drug influenced neuropathic pain, and examined its influence on inflammatory markers in relation to pain events. Outcomes from these trials appeared to suggest an association between the treatment and changes in pain severity scores for certain types of neuropathic pain.

Key Studies & References

1. Cyclooxygenase-2 Selective Inhibitors in the Management of Acute and Perioperative Pain

Common questions about Валсартан А (FAQ)

Q: Нужно ли принимать Валсартан А постоянно?

A: Valsartan is intended for the treatment of chronic conditions like high blood pressure and heart failure. Studies show that its blood pressure lowering effect is maintained during long-term follow-up, sometimes for two years or more. Therefore, the duration of your therapy is determined by a physician based on your long-term health needs.

Q: Может ли Валсартан А вызвать головокружение или усталость?

A: Yes, dizziness and fatigue or general weariness are commonly reported undesirable effects associated with Valsartan, according to the official product information. These effects are noted in regulatory documents as factors to be aware of during treatment.

Q: Может ли Валсартан А взаимодействовать с пищевыми добавками?

A: Valsartan is known to increase potassium levels in the blood. Regulatory documents list co-administration with potassium supplements as carrying a risk of hyperkalemia (high potassium levels). For this reason, caution is advised regarding their combined use.

Q: Нужно ли менять диету при приеме Валсартан А?

A: Valsartan can elevate potassium levels in the blood. Official product information notes that using salt substitutes containing potassium may increase blood potassium levels, which requires awareness during treatment.

Q: Можно ли принимать Валсартан А, если у меня диабет?

A: Official information confirms that Valsartan can be used by patients with diabetes. However, regulatory documents state that combining Valsartan with the medicine aliskiren is strictly contraindicated (not allowed) if the patient also has diabetes or kidney impairment.

Q: Как долго можно принимать Валсартан А?

A: The blood pressure lowering effects of Valsartan have been shown to be maintained for extended periods in clinical studies, sometimes for two years or more. Since it is for chronic conditions, the ultimate duration of your therapy is determined by a physician.

Q: Какая доза Валсартан А используется в большинстве исследований?

A: Regulatory documents indicate that 80 mg once daily is a common dose used in clinical practice and studies for hypertension. Other dosages, including 160 mg and 320 mg, were also used in trials to demonstrate the medicine's effect in reducing blood pressure.

Q: Можно ли водить машину, принимая Валсартан А?

A: While specific driving studies have not been performed, official information advises caution. This is because dizziness or weariness, which could impair your ability to drive or operate machinery, may occasionally occur during treatment with Valsartan.

Q: Помогает ли Валсартан А защищать от инсульта?

A: Valsartan is officially indicated for the treatment of high blood pressure (hypertension). The therapeutic goal of treating hypertension, which Valsartan achieves, is generally to reduce the overall risk of serious cardiovascular events, including stroke.

Q: Через сколько времени начинает действовать Валсартан А?

A: According to official pharmacological data, the blood pressure lowering activity begins quickly, around two hours after taking a single dose. The maximum reduction in blood pressure is typically achieved within six hours.

Q: Валсартан А и алкоголь — они совместимы?

A: Regulatory documents indicate that alcohol (ethanol) may have an additive effect on lowering blood pressure. This could increase the risk of side effects like lightheadedness, dizziness, or fainting when Valsartan is taken.

Q: Нужно ли принимать Валсартан А утром или вечером?

A: Regulatory documents state that the medicine is generally taken once daily and may be taken with or without food. Consistency in administration time helps maintain a steady effect.

Q: Может ли Валсартан А повлиять на половую функцию?

A: Erectile dysfunction (impotence) has been reported as an undesirable effect in the official product information, though it is not one of the most common issues listed.

Q: Какие бывают признаки передозировки Валсартан А?

A: If too much Valsartan is taken, regulatory documents warn that the primary sign is marked low blood pressure (hypotension). This severe drop in blood pressure could potentially lead to shock, circulatory collapse, and a depressed level of consciousness.

Q: Может ли Валсартан А вызвать бессонницу?

A: Yes, sleep disorders, including insomnia, are listed as uncommon undesirable effects in the official product information.

Q: Влияет ли Валсартан А на уровень сахара в крови?

A: While Valsartan alone does not typically alter blood sugar tolerance, its use with aliskiren is contraindicated in diabetic patients. This combination requires careful monitoring for patients in this group.

Q: Может ли Валсартан А повлиять на настроение?

A: Yes, official safety information indicates that mood swings or feelings of depression have been reported as uncommon undesirable effects during treatment with Valsartan.

Q: Можно ли принимать Валсартан А с грейпфрутовым соком?

A: Valsartan alone does not have a specific warning about interaction with grapefruit juice in its official monograph. However, combination products containing amlodipine typically carry a warning to avoid grapefruit juice.

Q: Влияет ли Валсартан А на способность к концентрации?

A: Trouble concentrating has been reported as a rare side effect in official safety data. This is in addition to the risk of dizziness, which could also temporarily impair concentration.

Q: Где можно найти официальную инструкцию по применению Валсартан А?

A: The complete, official prescribing information (e.g., Summary of Product Characteristics or Package Leaflet) is available on the website of your national drug regulatory authority (e.g., EMA, FDA, MHRA). You can also obtain a copy from your dispensing pharmacist.

How to Store and Dispose of Valsartan

Proper storage and disposal are essential to maintain the efficacy of Valsartan and ensure safety.

Storage

• Keep Valsartan tablets in the container they were provided in, tightly closed.
• Store the medication at room temperature, away from excessive heat and moisture. Do not store it in the bathroom.
• Keep all forms of Valsartan out of the sight and reach of children and pets.

Disposal

• Do not use or keep outdated medicine. Dispose of it properly.
• The best method for disposal of most unused or expired medication is through a drug take-back program or a medicine mail-back program.
• If a take-back option is unavailable, you may discard the medicine in your household trash after mixing it with an undesirable substance (such as dirt or used coffee grounds) and placing the mixture in a sealed bag or container. This makes it less appealing to children and pets. Do not flush Valsartan down the toilet unless specifically instructed by an authority.